Arrowhead Pharmaceuticals, Inc. (ARWR) financials: revenue, earnings and cash flow
Fiscal 2017–2026 · from SEC filings · data as of November 13, 2026
Summary
Arrowhead Pharmaceuticals’s revenue went from $31M in fiscal 2017 to $451M in fiscal 2026, growth of about 34.4% a year.
Net income in fiscal 2026 was -$724M, a net margin of -160.6%; the best year in this period was 2019 with $68M.
Free cash flow was -$284M in fiscal 2026 and positive in 3 of the 10 years shown.
The diluted share count rose 92% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $451M | $829M | $4M | $241M | $243M | $138M | $88M | $169M | $16M | $31M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$707M | $98M | -$601M | -$205M | -$179M | -$149M | -$93M | $61M | -$56M | -$37M |
| Net income | -$724M | -$2M | -$599M | -$205M | -$176M | -$141M | -$85M | $68M | -$54M | -$34M |
| EPS (diluted) | $-5.11 | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 | $-0.84 | $0.69 | $-0.65 | $-0.47 |
| R&D | $739M | $607M | $506M | $353M | $297M | $206M | $129M | $81M | $53M | $51M |
| Revenue growth | −45.6% | +23258.2% | −98.5% | −1.0% | +75.9% | +57.2% | −47.9% | +945.7% | −48.6% | +19736.5% |
Cash flow
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$272M | $180M | -$463M | -$154M | -$136M | $171M | -$96M | $173M | -$47M | -$24M |
| Capital spending | -$12M | -$23M | -$141M | -$177M | -$53M | -$24M | -$12M | -$12M | -$1M | -$8M |
| Free cash flow | -$284M | $157M | -$604M | -$331M | -$189M | $148M | -$108M | $161M | -$49M | -$32M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $68M | $63M | $74M | $78M | $121M | $77M | $43M | $12M | $8M | $8M |
Balance sheet
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | $1.2B | $919M | $681M | $404M | $108M | $311M | $229M | $259M | $77M | $66M |
| Debt | $845M | $151M | $511M | $115M | $82M | $26M | $21M | — | $2M | $3M |
| Equity | $50M | $466M | $185M | $271M | $399M | $409M | $462M | $245M | $96M | $81M |
| Total assets | $1.7B | $1.4B | $1.1B | $766M | $692M | $710M | $523M | $350M | $112M | $104M |
| Shares (diluted) | 142M | 134M | 120M | 107M | 105M | 104M | 101M | 99M | 84M | 74M |
Margins and returns
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | -156.9% | 11.9% | -16927.1% | -85.2% | -73.4% | -107.8% | -105.9% | 36.2% | -346.5% | -117.8% |
| Net margin | -160.6% | -0.2% | -16882.4% | -85.3% | -72.4% | -101.8% | -96.1% | 40.3% | -337.3% | -109.5% |
| FCF margin | -63.0% | 18.9% | -17018.3% | -137.3% | -77.7% | 106.8% | -122.5% | 95.4% | -301.4% | -101.4% |
| ROIC | -78.3% | 9.3% | -86.0% | -41.9% | -29.4% | -27.1% | -15.2% | 24.9% | -45.0% | -34.8% |
| ROE | -1439.4% | -0.4% | -323.3% | -75.6% | -44.2% | -34.4% | -18.3% | 27.8% | -56.8% | -42.2% |
Frequently asked questions
What is Arrowhead Pharmaceuticals’s annual revenue?
$451M in fiscal 2026.
How much profit does Arrowhead Pharmaceuticals make?
Net income was -$724M in fiscal 2026 (net margin -160.6%).
Is Arrowhead Pharmaceuticals’s revenue growing?
No: revenue fell 45.6% in fiscal 2026 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.